Access cutting-edge cancer treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Access cancer specialists in New Haven at no cost
This study follows strict safety protocols and ethical guidelines
All study-related cancer treatment provided free
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.
Sponsor: Iovance Biotherapeutics, Inc.
Check if you qualify for this cancer clinical trial in New Haven, CT
If you're searching for cancer treatment options in New Haven, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.